Collaboration partners are important to our business model. They help us to spread the financial cost of our development programmes and mitigate the risk to our business by enabling us to pursue multiple programmes for the same research spend. In addition we are able to access our partners’ specialist research expertise.
We currently have the following co-development collaborations:
|Hebei Medical University Biomedical Engineering Center (HMUBEC)||Aurora+FLT3|
|SRI International||TYK2 (Autoimmune)|
HMUBEC is an independent research centre operating within Hebei Medical University Science & Technology General Company (HMUSTGC). Its capabilities include GLP compliant laboratories, CGMP compliant manufacturing capabilities and well-established sales distribution channels in Greater China. HMUSTGC has successfully developed more than 85 therapeutic products and medical devices for the Chinese market since its formation in 1992.
HMUBEC is fully funding the pre-clinical development of the Aurora+FLT3 programme to international standards. This significantly reduces the cost and risk to Sareum and provides us with HMU’s drug development expertise and access to the Chinese market.
SRI is a non-profit research and development institute based in Silicon Valley. It brings its innovations to the marketplace through technology licensing, new products, and spin-off ventures. SRI's Biosciences division carries out drug discovery research and development to advance programmes towards in-human clinical trials. Its product pipeline has yielded marketed drugs and therapeutics currently in clinical trials.
In addition to funding the programme biology, the collaboration with SRI gives Sareum access to world-class autoimmune disease biology and drug development expertise.